Or maybe they've inadvertently discovered an obesity-enhancing drug!
Seriously though, without seeing the exact protocol, controls, and actual data, in sufficient detail so that another expert could repeat the study, no announced "result" has any meaningful interpretation.
Real drug-development teams don't PR every little baby-step. Just key development and regulatory milestones. Those are the only events that significantly affect valuation.
Besides, the entire premise of NNVC was that they were beyond the "discovery phase" 15 years ago, and had a platform that could churn out new candidates every few weeks to run through the FDA gauntlet.